Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.77) per share. This is a 7.23 percent increase over losses of $(0.83) per share from the same period last year.
Rhythm Pharmaceuticals Presents Data From Its Long-term Extension Study Of Setmelanotide Showing Sustained And Deepened BMI Reduction In Patients With Hypothalamic Obesity At One Year At ObesityWeek 2023
-- Patients with hypothalamic obesity (n=12) achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment -- -- Three of 11 pediatric patients with hypothalamic obesity achieved normal weight at one
